Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. Konner on Bevacizumab in Ovarian Cancer

November 16th 2012

Jason A. Konner, MD, from Memorial Sloan-Kettering Cancer Center, explains that one of the main drivers behind research into bevacizumab in ovarian cancer is to identify which patients will benefit the most from the treatment.

Dr. Markman Discusses the Phase III AURELIA Trial

October 29th 2012

Maurie Markman, MD, from Cancer Treatment Centers of America, discusses the AURELIA trial that examined the addition of bevacizumab to chemotherapy for women with platinum-resistant recurrent ovarian cancer.

Bevacizumab Plus Chemotherapy Improves Response Rates and PFS in Platinum-Resistant Ovarian Cancer

October 2nd 2012

An exploratory analysis of the phase III AURELIA trial affirms the benefit of adding bevacizumab to chemotherapy for patients with platinum-resistant recurrent ovarian cancer.

New Chemotherapy Strategy Emerges in Ovarian Cancer

September 24th 2012

A study evaluating first-line chemotherapy dosing strategies for treating patients with advanced epithelial ovarian cancer has delivered practice-changing findings.

Maintenance Erlotinib Fails to Improve Survival in Ovarian Cancer

July 31st 2012

Erlotinib given as a maintenance therapy did not improve PFS or OS in patients with epithelial ovarian cancer who had received first-line platinum-based chemotherapy.

Multidisciplinary Approaches Are Needed in Ovarian Cancer

July 23rd 2012

While ovarian cancer survival rates have improved slightly since the 1970s, the overall five-year survival for patients diagnosed with the tumor type lags behind the average rate of all cancers.

Dr. Bast Discusses Biomarkers for Ovarian Cancer

July 19th 2012

Dr. Robert Bast, from the MD Anderson Cancer Center, Discusses New Biomarker Panels for Ovarian Cancer Screening.

Modified IP Regimen for Ovarian Cancer Leads to 90% Completion Rate

July 18th 2012

A modified intraperitoneal (IP) regimen for advanced ovarian cancer demonstrated feasibility, tolerability, and evidence of effectiveness, results of a small pilot study suggest.

Close Call for Cost-Effectiveness of Bevacizumab in Ovarian Cancer

July 9th 2012

Recent clinical and economic studies have suggested that ovarian cancer regimens containing bevacizumab could fall within the boundaries of cost-effectiveness, at least for some patients.

Paclitaxel Shortage May Add Millions to Cost of Ovarian Cancer Care

June 27th 2012

A chronic shortage of the most commonly used taxane for ovarian cancer would add almost $9 million a month to the cost of care if half of newly diagnosed cases were affected.

Dr. Pujade-Lauraine on the AURELIA Bevacizumab Trial

June 2nd 2012

Dr. Eric Pujade-Lauraine, from Université de Paris Descartes, France, on the AURELIA Bevacizumab Trial for Platinum-Resistant Ovarian Cancer.

Avastin Delays Disease Progression in Platinum-Resistant Ovarian Cancer

June 2nd 2012

Combining bevacizumab with standard chemotherapy reduced the risk of disease progression by 52% in patients with platinum-resistant ovarian cancer.

Dr. Davidson on Screening for Ovarian Cancer

May 23rd 2012

Dr. Nancy Davidson, from the University of Pittsburgh Cancer Institute, on Screening for Ovarian Cancer

Hereditary Breast and Ovarian Cancer: Which Patients Are at High Risk?

May 23rd 2012

Detecting hereditary cancer and providing genetic counseling can help prevent a new primary cancer and may also help to protect family members from developing cancer.

NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care

May 23rd 2012

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

Genetic Assessment of Breast and Ovarian Cancer Risk

April 30th 2012

Understanding the genetic basis of breast and ovarian cancers is essential to providing patients with effective preventive and/or management strategies that can improve outcomes.

PARP Inhibitors Intriguing Despite Research Setbacks

April 26th 2012

Despite initial disappointing findings on overall survival, PARP inhibitors remains under active investigation for patients with ovarian cancer.

Supreme Court Asks for Reconsideration on BRCA1 and BRCA2 Patents

March 27th 2012

The US Supreme Court has asked an appellate court to reconsider its decision regarding patents held on two genes.

Improved Survival in Women With Invasive Epithelial Ovarian Cancer and Germline BRCA Gene Mutations

March 26th 2012

Researchers are reporting better survival rates in women with invasive EOC and germline mutations in the tumor suppressor genes BRCA1 and BRCA2 than in patients who are noncarriers.

Dr. Birrer on the Ovarian Cancer Avastin OS Benefit

March 2nd 2012

Dr. Michael Birrer from Massachusetts General Hospital Cancer Center on the Ovarian Cancer Avastin OS Benefit

NEXT PAGE
PREVIOUS PAGE